|
CN101198698B
(zh)
|
2005-03-31 |
2014-03-19 |
中外制药株式会社 |
通过调节多肽缔合制备多肽的方法
|
|
IN2014DN10515A
(es)
|
2006-03-31 |
2015-08-21 |
Chugai Pharmaceutical Co Ltd |
|
|
DK2009101T3
(en)
|
2006-03-31 |
2018-01-15 |
Chugai Pharmaceutical Co Ltd |
Antibody modification method for purification of a bispecific antibody
|
|
WO2008119353A1
(en)
|
2007-03-29 |
2008-10-09 |
Genmab A/S |
Bispecific antibodies and methods for production thereof
|
|
JP5334319B2
(ja)
|
2007-09-26 |
2013-11-06 |
中外製薬株式会社 |
Cdrのアミノ酸置換により抗体の等電点を改変する方法
|
|
KR101922788B1
(ko)
|
2007-09-26 |
2018-11-27 |
추가이 세이야쿠 가부시키가이샤 |
항체 정상영역 개변체
|
|
US20120071634A1
(en)
|
2009-03-19 |
2012-03-22 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody Constant Region Variant
|
|
WO2010107110A1
(ja)
|
2009-03-19 |
2010-09-23 |
中外製薬株式会社 |
抗体定常領域改変体
|
|
EP2414391B1
(en)
|
2009-04-02 |
2018-11-28 |
Roche Glycart AG |
Multispecific antibodies comprising full length antibodies and single chain fab fragments
|
|
WO2011028952A1
(en)
|
2009-09-02 |
2011-03-10 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
|
EP2481752B1
(en)
|
2009-09-24 |
2016-11-09 |
Chugai Seiyaku Kabushiki Kaisha |
Modified antibody constant regions
|
|
EP2543730B1
(en)
|
2010-03-04 |
2018-10-31 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody constant region variant
|
|
TW201138821A
(en)
|
2010-03-26 |
2011-11-16 |
Roche Glycart Ag |
Bispecific antibodies
|
|
BR112012027001A2
(pt)
*
|
2010-04-23 |
2016-07-19 |
Genentech Inc |
produção de proteínas heteromultiméricas
|
|
JP5953303B2
(ja)
|
2010-07-29 |
2016-07-20 |
ゼンコア インコーポレイテッド |
改変された等電点を有する抗体
|
|
WO2012025530A1
(en)
|
2010-08-24 |
2012-03-01 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies comprising a disulfide stabilized - fv fragment
|
|
HUE047228T2
(hu)
|
2010-11-05 |
2020-04-28 |
Zymeworks Inc |
Stabil heterodimer antitest-kialakítás az FC doménben mutációval
|
|
KR101962483B1
(ko)
|
2010-11-17 |
2019-03-29 |
추가이 세이야쿠 가부시키가이샤 |
혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자
|
|
PT2647707T
(pt)
|
2010-11-30 |
2018-11-15 |
Chugai Pharmaceutical Co Ltd |
Agente terapêutico indutor de toxicidade
|
|
EP2655413B1
(en)
|
2010-12-23 |
2019-01-16 |
F.Hoffmann-La Roche Ag |
Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
|
|
CN103732628B
(zh)
|
2011-03-03 |
2017-06-23 |
酵活有限公司 |
多价杂多聚体骨架设计和构建体
|
|
US9062106B2
(en)
|
2011-04-27 |
2015-06-23 |
Abbvie Inc. |
Methods for controlling the galactosylation profile of recombinantly-expressed proteins
|
|
WO2013040429A1
(en)
|
2011-09-14 |
2013-03-21 |
Rana Therapeutics Inc. |
Multimeric oligonucleotide compounds
|
|
US12466897B2
(en)
|
2011-10-10 |
2025-11-11 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
HK1202878A1
(en)
|
2011-10-11 |
2015-10-09 |
F. Hoffmann-La Roche Ag |
Improved assembly of bispecific antibodies
|
|
KR102049803B1
(ko)
*
|
2011-10-27 |
2019-11-29 |
젠맵 에이/에스 |
이종이량체 단백질의 생산
|
|
KR102398736B1
(ko)
|
2011-10-31 |
2022-05-16 |
추가이 세이야쿠 가부시키가이샤 |
중쇄와 경쇄의 회합이 제어된 항원 결합 분자
|
|
JP6326371B2
(ja)
|
2011-11-04 |
2018-05-16 |
ザイムワークス,インコーポレイテッド |
Fcドメインにおける変異を有する安定なヘテロ二量体抗体デザイン
|
|
SG11201402485UA
(en)
|
2011-11-21 |
2014-06-27 |
Genentech Inc |
Purification of anti-c-met antibodies
|
|
RS60499B1
(sr)
*
|
2011-12-20 |
2020-08-31 |
Medimmune Llc |
Modifikovani polipeptidi za bispecifične skelete antitela
|
|
MX360453B
(es)
|
2011-12-22 |
2018-11-01 |
Genentech Inc |
Cromatografia de membrana de intercambio ionico.
|
|
JP6486686B2
(ja)
|
2012-02-10 |
2019-03-20 |
ジェネンテック, インコーポレイテッド |
単鎖抗体及び他のヘテロ多量体
|
|
US9067990B2
(en)
|
2013-03-14 |
2015-06-30 |
Abbvie, Inc. |
Protein purification using displacement chromatography
|
|
US9334319B2
(en)
|
2012-04-20 |
2016-05-10 |
Abbvie Inc. |
Low acidic species compositions
|
|
US9181572B2
(en)
|
2012-04-20 |
2015-11-10 |
Abbvie, Inc. |
Methods to modulate lysine variant distribution
|
|
KR102023401B1
(ko)
|
2012-05-10 |
2019-11-04 |
바이오아트라, 엘엘씨 |
다중-특이적 모노클로날 항체
|
|
CN104379604A
(zh)
*
|
2012-05-24 |
2015-02-25 |
弗·哈夫曼-拉罗切有限公司 |
多特异性抗体
|
|
US9249182B2
(en)
|
2012-05-24 |
2016-02-02 |
Abbvie, Inc. |
Purification of antibodies using hydrophobic interaction chromatography
|
|
JP6628966B2
(ja)
|
2012-06-14 |
2020-01-15 |
中外製薬株式会社 |
改変されたFc領域を含む抗原結合分子
|
|
US9499634B2
(en)
|
2012-06-25 |
2016-11-22 |
Zymeworks Inc. |
Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
|
|
RU2639287C2
(ru)
|
2012-06-27 |
2017-12-20 |
Ф. Хоффманн-Ля Рош Аг |
Способ отбора и получения высокоселективных и мультиспецифичных нацеливающих групп с заданными свойствами, включающих по меньшей мере две различные связывающие группировки, и их применения
|
|
BR112014028368A2
(pt)
|
2012-06-27 |
2017-11-14 |
Hoffmann La Roche |
método de produção de conjugado de região fc de anticorpo, conjugado de região fc de anticorpo e formulação farmacêutica
|
|
CN104768571B
(zh)
|
2012-07-13 |
2018-11-09 |
酵活有限公司 |
多价异多聚体支架设计和构建体
|
|
AU2013289883B2
(en)
*
|
2012-07-13 |
2018-11-01 |
Zymeworks Bc Inc. |
Bispecific asymmetric heterodimers comprising anti-CD3 constructs
|
|
US9206390B2
(en)
|
2012-09-02 |
2015-12-08 |
Abbvie, Inc. |
Methods to control protein heterogeneity
|
|
US9512214B2
(en)
|
2012-09-02 |
2016-12-06 |
Abbvie, Inc. |
Methods to control protein heterogeneity
|
|
EP2893343B1
(en)
|
2012-09-07 |
2019-11-20 |
The Governors of the University of Alberta |
Methods for diagnosis of inflammatory liver disease
|
|
WO2014043544A1
(en)
*
|
2012-09-14 |
2014-03-20 |
Rana Therapeutics, Inc. |
Multimeric oligonucleotide compounds
|
|
KR20140036905A
(ko)
*
|
2012-09-18 |
2014-03-26 |
삼성전자주식회사 |
이중특이 항체를 포함하는 단백질 복합체
|
|
US9695228B2
(en)
*
|
2012-11-21 |
2017-07-04 |
Janssen Biotech, Inc. |
EGFR and c-Met fibronectin type III domain binding molecules
|
|
US9914785B2
(en)
|
2012-11-28 |
2018-03-13 |
Zymeworks Inc. |
Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
|
|
KR102264570B1
(ko)
|
2012-11-28 |
2021-06-14 |
자임워크스 인코포레이티드 |
가공된 면역글로불린 중쇄-경쇄 쌍 및 이들의 용도
|
|
EP2940032B1
(en)
*
|
2012-12-27 |
2018-04-25 |
Spiber Inc. |
Extraction method for hydrophilic recombinant protein
|
|
JP6077570B2
(ja)
*
|
2012-12-27 |
2017-02-08 |
Spiber株式会社 |
親水性組換えタンパク質の粗精製方法
|
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10738132B2
(en)
|
2013-01-14 |
2020-08-11 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
|
CA2897987A1
(en)
|
2013-01-15 |
2014-07-24 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
|
US10533054B2
(en)
|
2013-01-31 |
2020-01-14 |
Thomas Jefferson University |
Agonist fusion protein for CD40 and OX40 and methods of stimulating the immune system
|
|
SG11201507230PA
(en)
|
2013-03-12 |
2015-10-29 |
Abbvie Inc |
Human antibodies that bind human tnf-alpha and methods of preparing the same
|
|
US8921526B2
(en)
|
2013-03-14 |
2014-12-30 |
Abbvie, Inc. |
Mutated anti-TNFα antibodies and methods of their use
|
|
WO2014151878A2
(en)
|
2013-03-14 |
2014-09-25 |
Abbvie Inc. |
Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
|
|
US9017687B1
(en)
|
2013-10-18 |
2015-04-28 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same using displacement chromatography
|
|
SI2968520T1
(sl)
*
|
2013-03-14 |
2022-01-31 |
Macrogenics, Inc. |
Bispecifične molekule, ki so imunoreaktivne z imunskimi efektorskimi celicami, ki izražajo aktivacijski receptor
|
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10160793B2
(en)
|
2013-03-15 |
2018-12-25 |
Genentech, Inc. |
Methods of treating inflammatory bowel disease using IL-22 Fc fusion proteins
|
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
|
AU2014232416B2
(en)
|
2013-03-15 |
2017-09-28 |
Xencor, Inc. |
Modulation of T Cells with Bispecific Antibodies and FC Fusions
|
|
KR102049990B1
(ko)
*
|
2013-03-28 |
2019-12-03 |
삼성전자주식회사 |
c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
|
|
HK1220919A1
(zh)
*
|
2013-04-05 |
2017-05-19 |
F. Hoffmann-La Roche Ag |
抗il-4抗体和双特异性抗体及其用途
|
|
JP5782580B2
(ja)
|
2013-04-25 |
2015-09-24 |
Spiber株式会社 |
ポリペプチドヒドロゲル及びその製造方法
|
|
US10065997B2
(en)
|
2013-04-25 |
2018-09-04 |
Spiber Inc. |
Polypeptide porous body and method for producing same
|
|
US10633453B2
(en)
*
|
2013-05-28 |
2020-04-28 |
Kaohsiung Medical University |
Antibody locker for the inactivation of protein drug
|
|
US9879081B2
(en)
*
|
2013-06-25 |
2018-01-30 |
Samsung Electronics Co., Ltd. |
Protein complex, bispecific antibody including the protein complex, and method of preparation thereof
|
|
US10370776B2
(en)
*
|
2013-09-25 |
2019-08-06 |
Idea Orchard, Llc |
Antibody like protein
|
|
WO2015048312A1
(en)
|
2013-09-26 |
2015-04-02 |
Costim Pharmaceuticals Inc. |
Methods for treating hematologic cancers
|
|
RU2730594C2
(ru)
|
2013-09-27 |
2020-08-24 |
Чугаи Сейяку Кабусики Кайся |
Способ получения полипептидного гетеромультимера
|
|
WO2015051293A2
(en)
|
2013-10-04 |
2015-04-09 |
Abbvie, Inc. |
Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
|
|
MX378238B
(es)
|
2013-10-14 |
2025-03-10 |
Janssen Biotech Inc |
Moléculas de unión con dominios de fibronectina de tipo iii modificadas con cisteína.
|
|
US8946395B1
(en)
|
2013-10-18 |
2015-02-03 |
Abbvie Inc. |
Purification of proteins using hydrophobic interaction chromatography
|
|
US9085618B2
(en)
|
2013-10-18 |
2015-07-21 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same
|
|
US9181337B2
(en)
|
2013-10-18 |
2015-11-10 |
Abbvie, Inc. |
Modulated lysine variant species compositions and methods for producing and using the same
|
|
US20160280787A1
(en)
|
2013-11-11 |
2016-09-29 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule containing modified antibody variable region
|
|
US20150139988A1
(en)
|
2013-11-15 |
2015-05-21 |
Abbvie, Inc. |
Glycoengineered binding protein compositions
|
|
PT3074424T
(pt)
|
2013-11-27 |
2025-05-29 |
Zymeworks Bc Inc |
Construções de ligação a antigénio biespecíficas direcionadas a her2
|
|
TW201609805A
(zh)
*
|
2013-12-23 |
2016-03-16 |
美國禮來大藥廠 |
結合egfr及met之多功能抗體
|
|
KR102194142B1
(ko)
*
|
2014-01-20 |
2020-12-23 |
삼성전자주식회사 |
항 c-Met/항 EGFR 이중 특이 항체 및 c-Src 저해제를 포함하는 병용 투여용 약학 조성물
|
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
|
DK3105250T3
(da)
*
|
2014-02-10 |
2020-09-28 |
Igm Biosciences Inc |
Multispecifikke iga-bindingsmolekyler
|
|
WO2015127405A2
(en)
|
2014-02-21 |
2015-08-27 |
Genentech, Inc. |
Anti-il-13/il-17 bispecific antibodies and uses thereof
|
|
RS59853B1
(sr)
|
2014-03-14 |
2020-02-28 |
Novartis Ag |
Molekuli anti-lag-3 antitela i njihove upotrebe
|
|
MX385936B
(es)
|
2014-03-28 |
2025-03-11 |
Xencor Inc |
Anticuerpos biespecíficos que se unen a cd38 y cd3.
|
|
AU2015244814B2
(en)
|
2014-04-07 |
2020-12-24 |
Chugai Seiyaku Kabushiki Kaisha |
Immunoactivating antigen-binding molecule
|
|
EP3140392B1
(en)
*
|
2014-05-06 |
2023-07-26 |
F. Hoffmann-La Roche AG |
Production of heteromultimeric proteins using mammalian cells
|
|
EA201692287A1
(ru)
|
2014-05-13 |
2017-06-30 |
Чугаи Сеияку Кабушики Каиша |
Антигенсвязывающая молекула, перенаправляющая т-клетки на клетки, обладающие иммуносупрессорной функцией
|
|
BR112016027888A2
(pt)
|
2014-05-28 |
2017-10-24 |
Zymeworks Inc |
construto de polipeptídeo de ligação ao antígeno isolado, polinucleotídeo isolado ou um conjunto de polinucleotídeos isolados, vetor ou conjunto de vetores, célula isolada, composição farmacêutica, uso do construto, método para tratar um sujeito com uma doença ou distúrbio, método para obter um construto, método para preparar um construto, meio de armazenamento legível por computador, método para produzir um construto de polipeptídeo de ligação com antígeno bi-específico e método para preparar um construto de polipeptídeo de ligação com antígeno isolado
|
|
EP3152235B1
(en)
|
2014-05-29 |
2021-08-25 |
MacroGenics, Inc. |
Tri-specific binding molecules and methods of use thereof
|
|
TWI693232B
(zh)
|
2014-06-26 |
2020-05-11 |
美商宏觀基因股份有限公司 |
與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
|
|
CA2952727A1
(en)
|
2014-06-27 |
2015-12-30 |
Innate Pharma |
Multispecific nkp46 binding proteins
|
|
US11208480B2
(en)
|
2014-06-27 |
2021-12-28 |
Innate Pharma |
Multispecific antigen binding proteins
|
|
US9212225B1
(en)
|
2014-07-01 |
2015-12-15 |
Amphivena Therapeutics, Inc. |
Bispecific CD33 and CD3 binding proteins
|
|
CA2957387A1
(en)
*
|
2014-08-07 |
2016-02-11 |
Hyogo College Of Medicine |
Therapeutic agent for cancer which comprises combination of il-18 and molecule-targeting antibody
|
|
AU2015314744A1
(en)
|
2014-09-12 |
2017-03-02 |
Genentech, Inc. |
Anti-CLL-1 antibodies and immunoconjugates
|
|
HUE052460T2
(hu)
|
2014-09-12 |
2021-04-28 |
Genentech Inc |
Anti-HER2 antitestek és immunkonjugátumok
|
|
KR20170052600A
(ko)
|
2014-09-12 |
2017-05-12 |
제넨테크, 인크. |
시스테인 가공된 항체 및 콘주게이트
|
|
KR20170060042A
(ko)
|
2014-09-13 |
2017-05-31 |
노파르티스 아게 |
Alk 억제제의 조합 요법
|
|
WO2016044396A1
(en)
|
2014-09-17 |
2016-03-24 |
Genentech, Inc. |
Immunoconjugates comprising anti-her2 antibodies and pyrrolobenzodiazepines
|
|
MA40764A
(fr)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Agent thérapeutique induisant une cytotoxicité
|
|
KR20170063755A
(ko)
|
2014-09-26 |
2017-06-08 |
마크로제닉스, 인크. |
Cd19 및 cd3에 결합할 수 있는 이중-특이적 1가 디아바디, 및 그것의 사용
|
|
AU2015323860B2
(en)
|
2014-09-29 |
2021-05-27 |
Duke University |
Bispecific molecules comprising an HIV-1 envelope targeting arm
|
|
CA2966558C
(en)
|
2014-11-05 |
2024-03-12 |
Genentech, Inc. |
Methods of producing two chain proteins in bacteria
|
|
EP3753948A1
(en)
|
2014-11-05 |
2020-12-23 |
Genentech, Inc. |
Methods of producing two chain proteins in bacteria
|
|
US10093730B2
(en)
|
2014-11-10 |
2018-10-09 |
Genentech, Inc. |
Anti-interleukin-33 antibodies and uses thereof
|
|
EP3219724A4
(en)
|
2014-11-11 |
2018-09-26 |
Chugai Seiyaku Kabushiki Kaisha |
Library of antigen-binding molecules including modified antibody variable region
|
|
US11566082B2
(en)
|
2014-11-17 |
2023-01-31 |
Cytiva Bioprocess R&D Ab |
Mutated immunoglobulin-binding polypeptides
|
|
EP3221361B1
(en)
|
2014-11-19 |
2021-04-21 |
Genentech, Inc. |
Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use
|
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
|
IL252467B
(en)
|
2014-11-26 |
2022-06-01 |
Xencor Inc |
Heterodimeric antibodies that bind cd3 and cd38
|
|
PE20171324A1
(es)
|
2014-11-26 |
2017-09-11 |
Xencor Inc |
Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales
|
|
CN107001482B
(zh)
|
2014-12-03 |
2021-06-15 |
豪夫迈·罗氏有限公司 |
多特异性抗体
|
|
AU2015360579A1
(en)
|
2014-12-10 |
2017-05-18 |
Genentech, Inc. |
Blood brain barrier receptor antibodies and methods of use
|
|
WO2016105450A2
(en)
|
2014-12-22 |
2016-06-30 |
Xencor, Inc. |
Trispecific antibodies
|
|
CA2974807A1
(en)
|
2015-01-26 |
2016-08-04 |
Macrogenics, Inc. |
Multivalent molecules comprising dr5-binding domains
|
|
WO2016141387A1
(en)
|
2015-03-05 |
2016-09-09 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
|
ES2752054T3
(es)
*
|
2015-03-31 |
2020-04-02 |
Novimmune Sa |
Método para optimizar el ensamble y producción de complejos de proteínas heteromultiméricas
|
|
EP3279216A4
(en)
|
2015-04-01 |
2019-06-19 |
Chugai Seiyaku Kabushiki Kaisha |
PROCESS FOR PREPARING POLYPEPTIDE HETERO OLIGOMER
|
|
HK1249048A1
(zh)
|
2015-04-03 |
2018-10-26 |
Eureka Therapeutics, Inc. |
靶向afp肽/mhc复合体的构建体及其用途
|
|
AU2016245887B2
(en)
*
|
2015-04-10 |
2021-09-23 |
Adimab, Llc. |
Methods for purifying heterodimeric multispecific antibodies from parental homodimeric antibody species
|
|
GB201506869D0
(en)
*
|
2015-04-22 |
2015-06-03 |
Ucb Biopharma Sprl |
Method
|
|
AU2016271113B2
(en)
|
2015-05-29 |
2022-09-08 |
Amphivena Therapeutics, Inc. |
Methods of using bispecific CD33 and CD3 binding proteins
|
|
WO2016193497A1
(en)
|
2015-06-04 |
2016-12-08 |
Ospedale San Raffaele Srl |
Inhibitor of igfbp3/tmem219 axis and diabetes
|
|
US10682391B2
(en)
|
2015-06-04 |
2020-06-16 |
Ospedale San Raffaele Srl |
Inhibitors of IGFBP3 binding to TMEM219 for treatment of intestinal diseases
|
|
TWI773646B
(zh)
|
2015-06-08 |
2022-08-11 |
美商宏觀基因股份有限公司 |
結合lag-3的分子和其使用方法
|
|
WO2016207273A2
(en)
*
|
2015-06-23 |
2016-12-29 |
Innate Pharma |
Multispecific antigen binding proteins
|
|
AU2016284871B2
(en)
|
2015-06-23 |
2022-09-29 |
Innate Pharma |
Multispecific NK engager proteins
|
|
CR20200423A
(es)
|
2015-07-30 |
2021-01-20 |
Macrogenics Inc |
Moléculas de unión a pd-1 y métodos de uso de las mismas (divisional 2018-0062)
|
|
MX388197B
(es)
|
2015-08-21 |
2025-03-19 |
Hoffmann La Roche |
Método para la reducción de proteínas de células hospederas en cromatografía de afinidad.
|
|
MA43345A
(fr)
|
2015-10-02 |
2018-08-08 |
Hoffmann La Roche |
Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
|
|
CN116396393A
(zh)
|
2015-10-08 |
2023-07-07 |
酵活英属哥伦比亚省公司 |
包含κ和λ轻链的抗原结合多肽构建体及其用途
|
|
HK1251475A1
(zh)
|
2015-10-08 |
2019-02-01 |
Macrogenics, Inc. |
用於癌症治疗的联合疗法
|
|
MA43354A
(fr)
|
2015-10-16 |
2018-08-22 |
Genentech Inc |
Conjugués médicamenteux à pont disulfure encombré
|
|
MA45326A
(fr)
|
2015-10-20 |
2018-08-29 |
Genentech Inc |
Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
|
|
EP3368074A2
(en)
|
2015-10-30 |
2018-09-05 |
Hoffmann-La Roche AG |
Anti-factor d antibodies and conjugates
|
|
EP3371217B1
(en)
|
2015-11-08 |
2025-06-11 |
F. Hoffmann-La Roche AG |
Methods of screening for multispecific antibodies
|
|
WO2017086367A1
(ja)
|
2015-11-18 |
2017-05-26 |
中外製薬株式会社 |
免疫抑制機能を有する細胞に対するt細胞リダイレクト抗原結合分子を用いた併用療法
|
|
JP6925278B2
(ja)
|
2015-11-18 |
2021-08-25 |
中外製薬株式会社 |
液性免疫応答の増強方法
|
|
AU2016365742A1
(en)
|
2015-12-07 |
2018-06-21 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and PSMA
|
|
BR112018011781A2
(en)
|
2015-12-14 |
2018-12-04 |
Macrogenics, Inc. |
bispecific molecule having one or more epitope binding sites capable of immunospecific binding to (one) pd-1 epitope (s) and one or more epitope binding sites capable of immunospecific binding to (one) epitope (s) -4, and pharmaceutical composition
|
|
CN108368166B
(zh)
|
2015-12-28 |
2023-03-28 |
中外制药株式会社 |
提高含fc区多肽纯化效率的方法
|
|
SG11201804951SA
(en)
|
2015-12-30 |
2018-07-30 |
Genentech Inc |
Use of tryptophan derivatives for protein formulations
|
|
IL299759A
(en)
|
2015-12-30 |
2023-03-01 |
Genentech Inc |
Formulations with reduced polysorbate dissolution
|
|
UY37127A
(es)
|
2016-02-17 |
2017-08-31 |
Macrogenics Inc |
Moléculas de unión a ror1, y métodos de uso de las mismas
|
|
TW202342540A
(zh)
|
2016-03-14 |
2023-11-01 |
日商中外製藥股份有限公司 |
用於癌之治療的細胞傷害誘導治療劑
|
|
AU2017250358B2
(en)
|
2016-04-15 |
2023-06-01 |
Alpine Immune Sciences, Inc. |
ICOS ligand variant immunomodulatory proteins and uses thereof
|
|
MA43552A
(fr)
|
2016-04-15 |
2018-11-07 |
Alpine Immune Sciences Inc |
Protéines immunomodulatrices à variants de cd80 et leurs utilisations
|
|
GEAP202214922A
(en)
|
2016-04-15 |
2022-02-10 |
Macrogenics Inc |
Novel b7-h3 binding molecules, antibody drug conjugates thereof and usage thereof
|
|
NZ746002A
(en)
|
2016-04-28 |
2025-08-29 |
Chugai Pharmaceutical Co Ltd |
Antibody-containing preparation
|
|
US10889615B2
(en)
|
2016-05-11 |
2021-01-12 |
Cytiva Bioprocess R&D Ab |
Mutated immunoglobulin-binding polypeptides
|
|
JP7031934B2
(ja)
|
2016-05-11 |
2022-03-08 |
サイティバ・バイオプロセス・アールアンドディ・アクチボラグ |
分離マトリックス
|
|
US11753438B2
(en)
|
2016-05-11 |
2023-09-12 |
Cytiva Bioprocess R&D Ab |
Method of cleaning and/or sanitizing a separation matrix
|
|
US10654887B2
(en)
|
2016-05-11 |
2020-05-19 |
Ge Healthcare Bio-Process R&D Ab |
Separation matrix
|
|
CN109071613A
(zh)
|
2016-05-11 |
2018-12-21 |
通用电气医疗集团生物工艺研发股份公司 |
分离基质
|
|
US10703774B2
(en)
|
2016-09-30 |
2020-07-07 |
Ge Healthcare Bioprocess R&D Ab |
Separation method
|
|
JP7106187B2
(ja)
|
2016-05-11 |
2022-07-26 |
サイティバ・バイオプロセス・アールアンドディ・アクチボラグ |
分離マトリックスを保存する方法
|
|
US10730908B2
(en)
|
2016-05-11 |
2020-08-04 |
Ge Healthcare Bioprocess R&D Ab |
Separation method
|
|
ES2858151T3
(es)
|
2016-05-20 |
2021-09-29 |
Hoffmann La Roche |
Conjugados de PROTAC-anticuerpo y procedimientos de uso
|
|
EP3465221B1
(en)
|
2016-05-27 |
2020-07-22 |
H. Hoffnabb-La Roche Ag |
Bioanalytical method for the characterization of site-specific antibody-drug conjugates
|
|
SG10202001787QA
(en)
|
2016-06-02 |
2020-04-29 |
Abbvie Inc |
Glucocorticoid receptor agonist and immunoconjugates thereof
|
|
CN109476648B
(zh)
|
2016-06-06 |
2022-09-13 |
豪夫迈·罗氏有限公司 |
司维司群抗体-药物缀合物和使用方法
|
|
MX2018015592A
(es)
|
2016-06-14 |
2019-04-24 |
Xencor Inc |
Anticuerpos inhibidores de puntos de control biespecificos.
|
|
PL3472177T3
(pl)
|
2016-06-17 |
2024-11-25 |
F. Hoffmann-La Roche Ag |
Oczyszczanie przeciwciał wieloswoistych
|
|
MA45412A
(fr)
|
2016-06-21 |
2021-05-26 |
Janssen Biotech Inc |
Molécules de liaison au domaine de fibronectine de type iii modifiées par la cystéine
|
|
US10316088B2
(en)
|
2016-06-28 |
2019-06-11 |
Xencor, Inc. |
Heterodimeric antibodies that bind somatostatin receptor 2
|
|
WO2018014260A1
(en)
|
2016-07-20 |
2018-01-25 |
Nanjing Legend Biotech Co., Ltd. |
Multispecific antigen binding proteins and methods of use thereof
|
|
US11471488B2
(en)
|
2016-07-28 |
2022-10-18 |
Alpine Immune Sciences, Inc. |
CD155 variant immunomodulatory proteins and uses thereof
|
|
WO2018022946A1
(en)
|
2016-07-28 |
2018-02-01 |
Alpine Immune Sciences, Inc. |
Cd155 variant immunomodulatory proteins and uses thereof
|
|
US11834490B2
(en)
|
2016-07-28 |
2023-12-05 |
Alpine Immune Sciences, Inc. |
CD112 variant immunomodulatory proteins and uses thereof
|
|
KR102050463B1
(ko)
|
2016-08-10 |
2019-11-29 |
아주대학교산학협력단 |
항체 중쇄불변부위 이종이중체 (heterodimeric Fc)에 융합된 사이토카인 (heterodimeric Fc-fused cytokine) 및 이를 포함하는 약제학적 조성물
|
|
CN109689111B
(zh)
|
2016-08-11 |
2024-04-05 |
基因泰克公司 |
吡咯并苯并二氮杂䓬前药及其抗体缀合物
|
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
US12448411B2
(en)
|
2016-09-30 |
2025-10-21 |
Cytiva Bioprocess R&D Ab |
Separation method
|
|
JP7050770B2
(ja)
|
2016-10-05 |
2022-04-08 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
抗体薬物コンジュゲートの調製方法
|
|
WO2018068201A1
(en)
|
2016-10-11 |
2018-04-19 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against ctla-4
|
|
UA128669C2
(uk)
|
2016-10-14 |
2024-09-25 |
Ксенкор, Інк. |
ГЕТЕРОДИМЕРНИЙ Fc-ЗЛИТИЙ БІЛОК IL15/IL15Ra
|
|
AU2017363309A1
(en)
|
2016-11-23 |
2019-07-11 |
Bioverativ Therapeutics Inc. |
Mono- and bispecific antibodies binding to coagulation factor IX and coagulation factor X
|
|
RU2759952C2
(ru)
|
2016-12-14 |
2021-11-19 |
Янссен Байотек, Инк. |
Cd8a-связывающие домены типа iii фибронектина
|
|
WO2018111978A1
(en)
|
2016-12-14 |
2018-06-21 |
Janssen Biotech, Inc. |
Cd137 binding fibronectin type iii domains
|
|
EP3554535A4
(en)
|
2016-12-14 |
2020-10-21 |
Janssen Biotech, Inc. |
PD-L1 BINDING FIBRONECTIN TYPE III DOMAINS
|
|
IL267589B2
(en)
|
2016-12-23 |
2024-11-01 |
Macrogenics Inc |
Adam9-binding molecules, and methods of use thereof
|
|
CN110636856A
(zh)
*
|
2016-12-29 |
2019-12-31 |
财团法人生物技术开发中心 |
Klk6-介导的cns-特异性抗体前药激活
|
|
US11274157B2
(en)
|
2017-01-12 |
2022-03-15 |
Eureka Therapeutics, Inc. |
Constructs targeting histone H3 peptide/MHC complexes and uses thereof
|
|
MA47459A
(fr)
|
2017-02-10 |
2019-12-18 |
Hoffmann La Roche |
Anticorps anti-tryptase, compositions les contenant et leurs utilisations
|
|
CN110325209A
(zh)
|
2017-02-24 |
2019-10-11 |
宏观基因有限公司 |
能够结合cd137和肿瘤抗原的双特异性结合分子及其用途
|
|
KR20250083578A
(ko)
|
2017-03-16 |
2025-06-10 |
알파인 이뮨 사이언시즈, 인코포레이티드 |
Cd80 변이체 면역조절 단백질 및 그의 용도
|
|
WO2018170021A1
(en)
|
2017-03-16 |
2018-09-20 |
Alpine Immune Sciences, Inc. |
Pd-l1 variant immunomodulatory proteins and uses thereof
|
|
AU2018235835A1
(en)
|
2017-03-16 |
2019-09-05 |
Alpine Immune Sciences, Inc. |
PD-L2 variant immunomodulatory proteins and uses thereof
|
|
WO2018200586A1
(en)
|
2017-04-26 |
2018-11-01 |
Eureka Therapeutics, Inc. |
Constructs specifically recognizing glypican 3 and uses thereof
|
|
CN108866635B
(zh)
|
2017-05-09 |
2021-11-26 |
安升(上海)医药科技有限公司 |
多特异性蛋白药物及其文库、以及制备方法和应用
|
|
EP3645122A1
(en)
|
2017-06-30 |
2020-05-06 |
Xencor, Inc. |
Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and antigen binding domains
|
|
EP4442268A3
(en)
|
2017-10-10 |
2025-04-02 |
Alpine Immune Sciences, Inc. |
Ctla-4 variant immunomodulatory proteins and uses thereof
|
|
AU2018351000B2
(en)
|
2017-10-18 |
2023-11-30 |
Alpine Immune Sciences, Inc. |
Variant ICOS Ligand immunomodulatory proteins and related compositions and methods
|
|
CN111246885B
(zh)
|
2017-10-20 |
2024-06-11 |
豪夫迈·罗氏有限公司 |
从单特异性抗体生成多特异性抗体的方法
|
|
AU2018358883B2
(en)
|
2017-10-30 |
2025-09-25 |
F. Hoffmann-La Roche Ag |
Method for in vivo generation of multispecific antibodies from monospecific antibodies
|
|
CN119161488A
(zh)
|
2017-11-01 |
2024-12-20 |
中外制药株式会社 |
具有降低的生物活性的抗体变体和同种型
|
|
US11339221B2
(en)
|
2017-11-01 |
2022-05-24 |
Tufts Medical Center, Inc. |
Bispecific antibody constructs and methods of use
|
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
JP2021502100A
(ja)
|
2017-11-08 |
2021-01-28 |
ゼンコア インコーポレイテッド |
新規抗pd−1配列を用いた二重特異性および単一特異性抗体
|
|
PE20201286A1
(es)
|
2017-12-01 |
2020-11-24 |
Abbvie Inc |
Agonista del receptor de glucocorticoides e inmunoconjugados de este
|
|
US11952422B2
(en)
|
2017-12-05 |
2024-04-09 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule comprising altered antibody variable region binding CD3 and CD137
|
|
AU2018385409A1
(en)
|
2017-12-12 |
2020-07-02 |
Macrogenics Inc. |
Bispecific CD 16-binding molecules and their use in the treatment of disease
|
|
US11319355B2
(en)
|
2017-12-19 |
2022-05-03 |
Xencor, Inc. |
Engineered IL-2 Fc fusion proteins
|
|
CN111699198B
(zh)
|
2017-12-28 |
2023-09-05 |
南京传奇生物科技有限公司 |
针对tigit的单域抗体和其变体
|
|
EP3735417A1
(en)
|
2018-01-03 |
2020-11-11 |
Alpine Immune Sciences, Inc. |
Multi-domain immunomodulatory proteins and methods of use thereof
|
|
CA3084518A1
(en)
|
2018-01-15 |
2019-07-18 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against pd-1
|
|
MX2020007628A
(es)
|
2018-01-26 |
2020-10-12 |
Genentech Inc |
Composiciones y metodos de uso.
|
|
TWI835772B
(zh)
|
2018-01-26 |
2024-03-21 |
美商建南德克公司 |
Il-22fc融合蛋白及使用方法
|
|
MX2020008095A
(es)
*
|
2018-01-31 |
2020-09-24 |
Regeneron Pharma |
Sistemas y métodos para caracterizar variantes de tamaño y carga de impurezas de productos farmacológicos.
|
|
US12384847B2
(en)
|
2018-02-08 |
2025-08-12 |
Dragonfly Therapeutics, Inc. |
Cancer therapy involving an anti-PD1 antibody and a multi-specific binding protein that binds NKG2D, CD16, and a tumor-associated antigen
|
|
DK3749346T3
(da)
|
2018-02-08 |
2024-09-09 |
Dragonfly Therapeutics Inc |
Antistof variable domænekombinationer rettet mod nkg2d-receptoren
|
|
CN111787947A
(zh)
|
2018-02-09 |
2020-10-16 |
豪夫迈·罗氏有限公司 |
用于肥大细胞介导的炎性疾病的治疗和诊断方法
|
|
SG11202007572VA
(en)
|
2018-02-15 |
2020-09-29 |
Macrogenics Inc |
Variant cd3-binding domains and their use in combination therapies for the treatment of disease
|
|
SG11202007945UA
(en)
|
2018-02-20 |
2020-09-29 |
Dragonfly Therapeutics Inc |
Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use
|
|
CN111757751A
(zh)
|
2018-02-21 |
2020-10-09 |
豪夫迈·罗氏有限公司 |
用于使用IL-22 Fc融合蛋白的治疗的剂量方案
|
|
GB201805142D0
(en)
*
|
2018-03-29 |
2018-05-16 |
Ge Healthcare Bioprocess R&D Ab |
Separation method
|
|
CA3093034A1
(en)
|
2018-03-30 |
2019-10-03 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies against lag-3 and uses thereof
|
|
WO2019195623A2
(en)
|
2018-04-04 |
2019-10-10 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
|
KR20210003814A
(ko)
|
2018-04-18 |
2021-01-12 |
젠코어 인코포레이티드 |
IL-15/IL-15Rα Fc-융합 단백질 및 TIM-3 항원 결합 도메인을 함유하는 TIM-3 표적화 이종이량체 융합 단백질
|
|
CA3097593A1
(en)
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
|
|
CN110386978A
(zh)
*
|
2018-04-19 |
2019-10-29 |
上海多米瑞生物技术有限公司 |
大肠杆菌周质空间表达的蛋白的提取方法
|
|
JP2021525806A
(ja)
|
2018-06-01 |
2021-09-27 |
タユー ファシャ バイオテック メディカル グループ カンパニー, リミテッド |
疾患または状態を処置するための組成物およびそれらの使用
|
|
WO2019227490A1
(en)
|
2018-06-01 |
2019-12-05 |
Tayu Huaxia Biotech Medical Group Co., Ltd. |
Compositions and methods for imaging
|
|
KR20210009421A
(ko)
|
2018-06-14 |
2021-01-26 |
바이오아트라, 엘엘씨 |
다중 특이적 항체 구조체
|
|
US12065476B2
(en)
|
2018-06-15 |
2024-08-20 |
Alpine Immune Sciences, Inc. |
PD-1 variant immunomodulatory proteins and uses thereof
|
|
CN112469440B
(zh)
|
2018-06-18 |
2024-09-06 |
优瑞科生物技术公司 |
靶向前列腺特异性膜抗原(psma)的构建体和其用途
|
|
CA3106829A1
(en)
|
2018-08-03 |
2020-02-06 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule containing two antigen-binding domains that are linked to each other
|
|
BR112021002276A2
(pt)
|
2018-08-08 |
2021-05-04 |
Dragonfly Therapeutics, Inc. |
proteínas de ligação a nkg2d, cd16 e um antígeno associado ao tumor
|
|
PE20211860A1
(es)
|
2018-08-08 |
2021-09-21 |
Dragonfly Therapeutics Inc |
Proteinas de union multiespecificas que se unen a bcma, nkg2d y cd16 y metodos de uso
|
|
EA202091888A1
(ru)
|
2018-08-08 |
2020-10-23 |
Драгонфлай Терапьютикс, Инк. |
Вариабельные домены антител, нацеленные на рецептор nkg2d
|
|
AU2019319822A1
(en)
|
2018-08-08 |
2021-03-18 |
Genentech, Inc. |
Use of tryptophan derivatives and L-methionine for protein formulation
|
|
GB201814281D0
(en)
|
2018-09-03 |
2018-10-17 |
Femtogenix Ltd |
Cytotoxic agents
|
|
CN113260634A
(zh)
|
2018-09-28 |
2021-08-13 |
中外制药株式会社 |
包含改变的抗体可变区的抗原结合分子
|
|
EP3632929A1
(en)
|
2018-10-02 |
2020-04-08 |
Ospedale San Raffaele S.r.l. |
Antibodies and uses thereof
|
|
EP3861016A2
(en)
|
2018-10-03 |
2021-08-11 |
Xencor, Inc. |
Il-12 heterodimeric fc-fusion proteins
|
|
WO2020076970A1
(en)
|
2018-10-11 |
2020-04-16 |
Inhibrx, Inc. |
B7h3 single domain antibodies and therapeutic compositions thereof
|
|
TW202506736A
(zh)
|
2018-10-11 |
2025-02-16 |
美商因荷布瑞克斯生物科學公司 |
5t4單域抗體及其治療性組合物
|
|
WO2020077257A1
(en)
|
2018-10-11 |
2020-04-16 |
Inhibrx, Inc. |
Pd-1 single domain antibodies and therapeutic compositions thereof
|
|
CA3115089A1
(en)
|
2018-10-11 |
2020-04-16 |
Inhibrx, Inc. |
Dll3 single domain antibodies and therapeutic compositions thereof
|
|
JP7630426B2
(ja)
|
2018-10-23 |
2025-02-17 |
ドラゴンフライ セラピューティクス, インコーポレイテッド |
ヘテロ二量体fc融合タンパク質
|
|
CN113056287A
(zh)
|
2018-10-24 |
2021-06-29 |
豪夫迈·罗氏有限公司 |
缀合的化学降解诱导剂及使用方法
|
|
EP3877407A1
(en)
|
2018-11-05 |
2021-09-15 |
F. Hoffmann-La Roche AG |
Methods of producing two chain proteins in prokaryotic host cells
|
|
AU2019389151B2
(en)
|
2018-11-30 |
2025-07-24 |
Alpine Immune Sciences, Inc. |
CD86 variant immunomodulatory proteins and uses thereof
|
|
JP2022513198A
(ja)
|
2018-12-10 |
2022-02-07 |
ジェネンテック, インコーポレイテッド |
Fc含有タンパク質への部位特異的コンジュゲーションのための光架橋性ペプチド
|
|
TWI874341B
(zh)
|
2018-12-18 |
2025-03-01 |
美商健生生物科技公司 |
產生異二聚體抗體之方法
|
|
MX2021008022A
(es)
*
|
2019-01-07 |
2021-08-05 |
Shattuck Labs Inc |
Proteínas heterodiméricas para modular células t gamma delta.
|
|
JP7538130B2
(ja)
|
2019-01-23 |
2024-08-21 |
タユー ファシャ バイオテック メディカル グループ カンパニー, リミテッド |
抗pd-l1ダイアボディおよびその使用
|
|
GB201901197D0
(en)
|
2019-01-29 |
2019-03-20 |
Femtogenix Ltd |
G-A Crosslinking cytotoxic agents
|
|
CN114173875B
(zh)
|
2019-03-01 |
2025-04-15 |
Xencor股份有限公司 |
结合enpp3和cd3的异二聚抗体
|
|
CN110068491A
(zh)
*
|
2019-04-15 |
2019-07-30 |
湖北擎科生物科技有限公司 |
一种高灵敏度低背景考马斯亮蓝染色液及其使用方法
|
|
WO2021006328A1
(en)
|
2019-07-10 |
2021-01-14 |
Chugai Seiyaku Kabushiki Kaisha |
Claudin-6 binding molecules and uses thereof
|
|
WO2021011353A1
(en)
*
|
2019-07-12 |
2021-01-21 |
Proviva Therapeutics (Hong Kong) Limited |
Il-2 compositions and methods of use thereof
|
|
CA3147621A1
(en)
*
|
2019-07-18 |
2021-01-21 |
Memorial Sloan Kettering Cancer Center |
Methods and compositions for targeting tgf-.beta. signaling in cd4+ helper t cells for cancer immunotherapy
|
|
TW202118793A
(zh)
|
2019-07-26 |
2021-05-16 |
美商建南德克公司 |
以 IL-22 Fc 融合蛋白預防或治療移植物抗宿主疾病 (GVHD) 之投藥
|
|
CN114423454A
(zh)
|
2019-09-20 |
2022-04-29 |
豪夫迈·罗氏有限公司 |
抗类胰蛋白酶抗体的给药
|
|
WO2021076543A1
(en)
|
2019-10-14 |
2021-04-22 |
Aro Biotherapeutics Company |
Epcam binding fibronectin type iii domains
|
|
WO2021076546A1
(en)
|
2019-10-14 |
2021-04-22 |
Aro Biotherapeutics Company |
Cd71 binding fibronectin type iii domains
|
|
US11781138B2
(en)
|
2019-10-14 |
2023-10-10 |
Aro Biotherapeutics Company |
FN3 domain-siRNA conjugates and uses thereof
|
|
CN110964119A
(zh)
*
|
2019-12-05 |
2020-04-07 |
沣潮医药科技(上海)有限公司 |
抗疟二聚体免疫粘附素、药物组合物和用途
|
|
EP4097129A1
(en)
|
2020-01-29 |
2022-12-07 |
Inhibrx, Inc. |
Cd28 single domain antibodies and multivalent and multispecific constructs thereof
|
|
MX2022010228A
(es)
|
2020-02-21 |
2022-09-19 |
Macrogenics Inc |
Moleculas de union a cd137 y usos de las mismas.
|
|
EP4112642A4
(en)
|
2020-02-28 |
2024-06-26 |
Shanghai Henlius Biotech, Inc. |
ANTI-CD137 CONSTRUCTION AND ITS USE
|
|
EP4118114A1
(en)
|
2020-03-13 |
2023-01-18 |
Genentech, Inc. |
Anti-interleukin-33 antibodies and uses thereof
|
|
MX2022012091A
(es)
|
2020-03-31 |
2022-10-13 |
Chugai Pharmaceutical Co Ltd |
Moleculas de union al antigeno multiespecificas dirigidas a ligando de tipo delta 3 (dll3) y sus usos.
|
|
WO2021207662A1
(en)
|
2020-04-10 |
2021-10-14 |
Genentech, Inc. |
Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome
|
|
US12157771B2
(en)
|
2020-05-06 |
2024-12-03 |
Dragonfly Therapeutics, Inc. |
Proteins binding NKG2D, CD16 and CLEC12A
|
|
US11919956B2
(en)
|
2020-05-14 |
2024-03-05 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
|
|
WO2022010798A1
(en)
|
2020-07-06 |
2022-01-13 |
Kiromic BioPharma, Inc. |
Mesothelin isoform binding molecules and chimeric pd1 receptor molecules, cells containing the same and uses thereof
|
|
MX2023000888A
(es)
|
2020-07-21 |
2023-02-22 |
Genentech Inc |
Inductores quimicos de degradacion conjugados con anticuerpo de brm y metodos de estos.
|
|
GB2597532A
(en)
|
2020-07-28 |
2022-02-02 |
Femtogenix Ltd |
Cytotoxic compounds
|
|
KR20230166150A
(ko)
|
2020-08-19 |
2023-12-06 |
젠코어 인코포레이티드 |
항-cd28 조성물
|
|
AU2021342566A1
(en)
|
2020-09-21 |
2023-03-02 |
Genentech, Inc. |
Purification of multispecific antibodies
|
|
AU2021362007A1
(en)
|
2020-10-16 |
2023-06-22 |
Invisishield Technologies Ltd. |
Compositions for preventing or treating viral and other microbial infections
|
|
WO2022108627A1
(en)
|
2020-11-18 |
2022-05-27 |
Kiromic Biopharma, Inc.Kiromic Biopharma, Inc. |
Gamma-delta t cell manufacturing processes and chimeric pd1 receptor molecules
|
|
AR125581A1
(es)
|
2020-12-07 |
2023-08-02 |
UCB Biopharma SRL |
Anticuerpos multiespecíficos y combinaciones de anticuerpos
|
|
EP4301774A4
(en)
|
2021-03-03 |
2025-08-13 |
Dragonfly Therapeutics Inc |
METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN
|
|
JP2024511319A
(ja)
|
2021-03-09 |
2024-03-13 |
ゼンコア インコーポレイテッド |
Cd3及びcldn6に結合するヘテロ二量体抗体
|
|
KR20230154311A
(ko)
|
2021-03-10 |
2023-11-07 |
젠코어 인코포레이티드 |
Cd3 및 gpc3에 결합하는 이종이량체 항체
|
|
WO2022197877A1
(en)
|
2021-03-19 |
2022-09-22 |
Genentech, Inc. |
Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents
|
|
EP4314009A1
(en)
|
2021-03-31 |
2024-02-07 |
F. Hoffmann-La Roche AG |
Purification of antibodies by mixed mode chromatography
|
|
KR20240034160A
(ko)
|
2021-04-14 |
2024-03-13 |
에이알오 바이오테라퓨틱스 컴패니 |
Cd71 결합 피브로넥틴 3형 도메인
|
|
AU2022258584A1
(en)
|
2021-04-14 |
2023-10-12 |
Aro Biotherapeutics Company |
Fn3 domain-sirna conjugates and uses thereof
|
|
US12448451B2
(en)
|
2021-06-25 |
2025-10-21 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-CTLA-4 antibody and use thereof
|
|
CN117915950A
(zh)
*
|
2021-08-06 |
2024-04-19 |
甘李药业股份有限公司 |
一种多特异性抗体及其用途
|
|
JP2024534004A
(ja)
|
2021-08-13 |
2024-09-18 |
ジェネンテック, インコーポレイテッド |
抗トリプターゼ抗体のための投与量
|
|
WO2023086807A1
(en)
|
2021-11-10 |
2023-05-19 |
Genentech, Inc. |
Anti-interleukin-33 antibodies and uses thereof
|
|
US20250084169A1
(en)
|
2022-01-12 |
2025-03-13 |
Biomolecular Holdings Llc |
Nk/monocyte engagers
|
|
AR128331A1
(es)
|
2022-01-26 |
2024-04-17 |
Genentech Inc |
Inductores químicos de degradación conjugados con anticuerpos y métodos de estos
|
|
AR128330A1
(es)
|
2022-01-26 |
2024-04-17 |
Genentech Inc |
Inductores químicos de degradación conjugados con anticuerpo y métodos de estos
|
|
EP4490173A1
(en)
|
2022-03-07 |
2025-01-15 |
Alpine Immune Sciences, Inc. |
Immunomodulatory proteins of variant cd80 polypeptides, cell therapies thereof and related methods and uses
|
|
EP4508077A1
(en)
|
2022-04-14 |
2025-02-19 |
Invisishield Technologies Ltd. |
Compositions for preventing or treating influenza infections
|
|
CA3256035A1
(en)
|
2022-04-14 |
2023-10-19 |
Invisishield Technologies Ltd. |
COMPOSITIONS FOR PREVENTING OR TREATMENT OF CORONAVIRUS INFECTIONS
|
|
IL316990A
(en)
|
2022-05-23 |
2025-01-01 |
Cereius Inc |
HER2 binding agents and their uses
|
|
WO2024110905A1
(en)
|
2022-11-24 |
2024-05-30 |
Beigene, Ltd. |
Anti-cea antibody drug conjugates and methods of use
|
|
EP4648792A2
(en)
|
2023-01-09 |
2025-11-19 |
Odyssey Therapeutics, Inc. |
Anti-tnfr2 antigen-binding proteins and uses thereof
|
|
CN121293352A
(zh)
|
2023-01-19 |
2026-01-09 |
广州百济神州生物制药有限公司 |
抗cmet抗体及使用方法
|
|
TW202436357A
(zh)
|
2023-03-03 |
2024-09-16 |
瑞士商百濟神州瑞士有限責任公司 |
Muc1抗體及使用方法
|
|
WO2024183636A1
(en)
|
2023-03-03 |
2024-09-12 |
Beigene Switzerland Gmbh |
Cd16a antibodies and methods of use
|
|
KR20250156802A
(ko)
|
2023-03-03 |
2025-11-03 |
비원 메디슨즈 아이 게엠베하 |
Muc1 및 cd16a 항체 및 사용 방법
|
|
TW202436345A
(zh)
|
2023-03-06 |
2024-09-16 |
瑞士商百濟神州瑞士有限責任公司 |
抗cd3多特異性抗體及使用方法
|
|
AR132064A1
(es)
|
2023-03-06 |
2025-05-21 |
Beigene Switzerland Gmbh |
Anticuerpos anti-cldn6 y métodos de uso
|
|
TW202436353A
(zh)
|
2023-03-06 |
2024-09-16 |
瑞士商百濟神州瑞士有限責任公司 |
抗cldn6與抗cd3多重特異性抗體以及使用方法
|
|
WO2024192065A1
(en)
|
2023-03-14 |
2024-09-19 |
Odyssey Therapeutics, Inc. |
Anti-cd25 antigen-binding proteins and uses thereof
|
|
CN121263210A
(zh)
|
2023-04-17 |
2026-01-02 |
沛科生物公司 |
抗体和抗体-药物偶联物以及使用方法和合成工艺及中间体
|
|
TW202448951A
(zh)
|
2023-05-17 |
2024-12-16 |
美商奧迪希治療公司 |
經修飾之單域抗體
|
|
AU2024308381A1
(en)
|
2023-06-29 |
2025-11-20 |
Odyssey Therapeutics, Inc. |
Anti-trailr2 antigen-binding proteins and uses thereof
|
|
WO2025038492A1
(en)
|
2023-08-11 |
2025-02-20 |
Abalytics Oncology, Inc. |
Anti-ctla-4 antibodies and related binding molecules and methods and uses thereof
|
|
TW202530265A
(zh)
|
2023-10-13 |
2025-08-01 |
美商奧迪希治療公司 |
抗cdh17抗原結合蛋白及其用途
|
|
WO2025106634A1
(en)
|
2023-11-17 |
2025-05-22 |
Genentech, Inc. |
Mcl-1 inhibitor compounds and use in antibody drug conjugates
|
|
WO2025111402A1
(en)
|
2023-11-21 |
2025-05-30 |
Board Of Regents Of The University Of Nebraska |
Anti-amyloid beta antibodies and related compositions and methods thereof
|
|
TW202535949A
(zh)
|
2023-12-20 |
2025-09-16 |
美商必治妥美雅史谷比公司 |
靶向IL-18受體β(IL-18RB)之抗體及相關方法
|
|
WO2025199352A2
(en)
|
2024-03-20 |
2025-09-25 |
Juno Therapeutics, Inc. |
Antibodies specific for solute carrier family 34 member 2 (slc34a2)
|
|
WO2025217240A1
(en)
|
2024-04-10 |
2025-10-16 |
Odyssey Therapeutics, Inc. |
Anti-tnfr2 antigen-binding proteins and uses thereof
|
|
WO2025240670A2
(en)
|
2024-05-15 |
2025-11-20 |
Abalytics Oncology, Inc. |
Anti-pd-1 antibodies and related binding molecules and methods and uses thereof
|
|
WO2025238133A1
(en)
|
2024-05-17 |
2025-11-20 |
UCB Biopharma SRL |
Multispecific antibody with binding specificity for il-11 and il-17
|
|
CN118271465B
(zh)
*
|
2024-05-31 |
2024-09-03 |
内蒙古大学 |
Trx-SPRR2A蛋白及其在制备抗肿瘤药物中的应用
|
|
WO2025255558A2
(en)
|
2024-06-07 |
2025-12-11 |
Odyssey Therapeutics, Inc. |
Anti-thymic stromal lymphopoietin (tslp) antigen-binding proteins and uses thereof
|
|
WO2025255435A2
(en)
|
2024-06-07 |
2025-12-11 |
Odyssey Therapeutics, Inc. |
Antigen-binding proteins against serum albumin and uses thereof
|
|
WO2026006809A1
(en)
|
2024-06-27 |
2026-01-02 |
Odyssey Therapeutics, Inc. |
Multispecific molecules binding tnfr2 and cd25 and uses thereof
|
|
WO2026006708A2
(en)
|
2024-06-27 |
2026-01-02 |
Odyssey Therapeutics, Inc. |
Anti-cd25 antigen-binding proteins and uses thereof
|
|
WO2026021476A1
(en)
|
2024-07-24 |
2026-01-29 |
Beone Guangzhou Biologics Manufacturing Co., Ltd. |
Anti-cmet and anti-egfr multispecific antibody drug conjugates
|